Link Between Uric Acid to Lymphocyte Ratio and Adverse Functional Outcomes in Patients with Acute Ischemic Stroke
Overview
This study investigates the relationship between the uric acid to lymphocyte ratio (ULR) and clinical outcomes in patients with acute ischemic stroke (AIS). Elevated ULR is associated with poorer functional outcomes and increased all-cause mortality at both 3 months and 1 year post-stroke.
Background
Acute ischemic stroke (AIS) is a leading cause of disability and mortality, particularly in East Asian populations. Inflammation plays a critical role in the pathophysiology of AIS, and reliable biomarkers are needed for risk stratification and prognostic evaluation. The ULR may serve as a comprehensive indicator of both oxidative stress and immune dysfunction in AIS patients.
Data Highlights
ULR Quartile
mRS Score 2-6 (3 months)
mRS Score 3-6 (3 months)
All-Cause Mortality (3 months)
Highest
OR 1.33 (95% CI 1.15–1.53)
OR 1.35 (95% CI 1.16–1.57)
HR 1.97 (95% CI 1.22–3.18)
Key Findings
Patients in the highest ULR quartile had significantly higher odds of poor functional outcomes at 3 months.
Elevated ULR was associated with increased all-cause mortality at 3 months.
Similar associations were observed at the 1-year follow-up.
ULR integrates the effects of uric acid and lymphocyte counts, reflecting systemic inflammation and oxidative stress.
The study highlights the potential of ULR as a biomarker for risk stratification in AIS patients.
Clinical Implications
Healthcare professionals should consider the ULR as a potential biomarker for assessing the prognosis of patients with acute ischemic stroke. Monitoring ULR may aid in identifying patients at higher risk for poor functional outcomes and mortality, guiding clinical decision-making.
Conclusion
The findings suggest that elevated ULR is a significant predictor of adverse outcomes in AIS patients. Further research is warranted to validate these results and explore the clinical utility of ULR in stroke management.
